This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Apr 6;60(4):1585-1587.

doi: 10.1093/rheumatology/keab061.

Baricitinib set to join the Covid-19 therapeutic arsenal?

Tania Gudu¹, Carmel Stober¹, Andrew P Cope², Joseph Cheriyan^{3

4}, James Galloway², Ian B Wilkinson^{3

4}, Michalis Kostapanos^{4

5}, David Jayne⁶, Frances Hall¹

Affiliations

Affiliations

¹ Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
² Centre for Rheumatic Disease, King's College London, London, UK.
³ Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK.
⁴ Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, , Cambridge, UK.
⁵ Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK.
⁶ Department of Medicine, University of Cambridge, Cambridge, UK.

PMID: 33502499
PMCID: PMC7928625
DOI: 10.1093/rheumatology/keab061

Editorial

Baricitinib set to join the Covid-19 therapeutic arsenal?

Tania Gudu et al. Rheumatology (Oxford). 2021.

. 2021 Apr 6;60(4):1585-1587.

doi: 10.1093/rheumatology/keab061.

Authors

Tania Gudu¹, Carmel Stober¹, Andrew P Cope², Joseph Cheriyan^{3

4}, James Galloway², Ian B Wilkinson^{3

4}, Michalis Kostapanos^{4

5}, David Jayne⁶, Frances Hall¹

Affiliations

¹ Rheumatology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
² Centre for Rheumatic Disease, King's College London, London, UK.
³ Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK.
⁴ Division of Experimental Medicine & Immunotherapeutics, School of Clinical Medicine, University of Cambridge, , Cambridge, UK.
⁵ Cambridge University Hospitals NHS Foundation Trust, , Cambridge, UK.
⁶ Department of Medicine, University of Cambridge, Cambridge, UK.

PMID: 33502499
PMCID: PMC7928625
DOI: 10.1093/rheumatology/keab061

No abstract available

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1 — Fig. 1
Molecular targets of baricitinib Baricitinib inhibits several molecules, shown in the figure in red. These include Janus kinase proteins (JAK1 and JAK2) and closely related tyrosine kinase 2 (TYK2), which transduce signals through a range of type I and type II cytokine receptors. Baricitinib thereby has a broad suppressive effect across innate and adaptive immune pathways, including the acute phase response, antiviral response to interferons and lymphocyte proliferation and differentiation. Baricitinib also has a direct antiviral effect via inhibition of angiotensin-converting enzyme 2 (ACE2)-mediated enocytosis in clarthrin-coated pits.

See this image and copyright information in PMC

Comment in

Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?
Khan S. Khan S. Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386. Rheumatology (Oxford). 2021. PMID: 33895812 Free PMC article. No abstract available.

Similar articles

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, Monteil V, Lauschke VM, Mirazimi A, Youhanna S, Tan YJ, Baldanti F, Sarasini A, Terres JAR, Nickoloff BJ, Higgs RE, Rocha G, Byers NL, Schlichting DE, Nirula A, Cardoso A, Corbellino M; Sacco Baricitinib Study Group. Stebbing J, et al. EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24. EMBO Mol Med. 2020. PMID: 32473600 Free PMC article.
Baricitinib: From Rheumatoid Arthritis to COVID-19.
Assadiasl S, Fatahi Y, Mosharmovahed B, Mohebbi B, Nicknam MH. Assadiasl S, et al. J Clin Pharmacol. 2021 Oct;61(10):1274-1285. doi: 10.1002/jcph.1874. Epub 2021 Jun 12. J Clin Pharmacol. 2021. PMID: 33870531 Free PMC article. Review.
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.
Rommasi F, Nasiri MJ, Mirsaeidi M. Rommasi F, et al. Mol Cell Biochem. 2022 Mar;477(3):711-726. doi: 10.1007/s11010-021-04325-9. Epub 2022 Jan 11. Mol Cell Biochem. 2022. PMID: 35013850 Free PMC article. Review.
JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
Sakai H, Kamuro H, Tokunoh N, Izawa T, Tamiya S, Yamamoto A, Tanaka S, Okuzaki D, Ono C, Matsuura Y, Okada Y, Yoshioka Y, Fujio Y, Obana M. Sakai H, et al. Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F931-F941. doi: 10.1152/ajprenal.00011.2024. Epub 2024 Apr 18. Am J Physiol Renal Physiol. 2024. PMID: 38634132 Free PMC article.
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Stebbing J, Sánchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, Sommerauer C, Tiseo G, Ghiadoni L, Virdis A, Monzani F, Rizos LR, Forfori F, Avendaño Céspedes A, De Marco S, Carrozzi L, Lena F, Sánchez-Jurado PM, Lacerenza LG, Cesira N, Caldevilla Bernardo D, Perrella A, Niccoli L, Méndez LS, Matarrese D, Goletti D, Tan YJ, Monteil V, Dranitsaris G, Cantini F, Farcomeni A, Dutta S, Burley SK, Zhang H, Pistello M, Li W, Romero MM, Andrés Pretel F, Simón-Talero RS, García-Molina R, Kutter C, Felce JH, Nizami ZF, Miklosi AG, Penninger JM, Menichetti F, Mirazimi A, Abizanda P, Lauschke VM. Stebbing J, et al. Sci Adv. 2021 Jan 1;7(1):eabe4724. doi: 10.1126/sciadv.abe4724. Print 2021 Jan. Sci Adv. 2021. PMID: 33187978 Free PMC article.

See all similar articles

Cited by

Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?
Khan S. Khan S. Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386. Rheumatology (Oxford). 2021. PMID: 33895812 Free PMC article. No abstract available.
A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019.
Hashemian SMR, Farhadi T. Hashemian SMR, et al. Int J Crit Illn Inj Sci. 2023 Oct-Dec;13(4):192-198. doi: 10.4103/ijciis.ijciis_27_23. Epub 2023 Dec 26. Int J Crit Illn Inj Sci. 2023. PMID: 38292399 Free PMC article. Review.
What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19.
Miller AC, D'Silva YA. Miller AC, et al. Int J Crit Illn Inj Sci. 2021 Jul-Sep;11(3):109-111. doi: 10.4103/ijciis.ijciis_80_21. Epub 2021 Sep 25. Int J Crit Illn Inj Sci. 2021. PMID: 34760655 Free PMC article. No abstract available.
New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.
Marcuzzi A, Rimondi E, Melloni E, Gonelli A, Grasso AG, Barbi E, Maximova N. Marcuzzi A, et al. Pharmaceuticals (Basel). 2022 Mar 19;15(3):374. doi: 10.3390/ph15030374. Pharmaceuticals (Basel). 2022. PMID: 35337171 Free PMC article. Review.
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
Hall FC, Cheriyan J, Cope AP, Galloway J, Wilkinson I, Bond S, Norton S, Banham-Hall E, Bayes H, Kostapanos M, Nodale M, Petchey WG, Sheeran T, Underwood J, Jayne DR; TACTIC-R Investigators Group. Hall FC, et al. Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14. Lancet Respir Med. 2023. PMID: 37977159 Free PMC article. Clinical Trial.

References

1. Zhou T, Su TT, Mudianto T, Wang J.. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med 2020;217:e20200674. - PMC - PubMed
1. Jorgensen SCJ, Tse CLY, Burry L, Dresser LD.. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 2020;40:843–56. - PMC - PubMed
1. RECOVERY Collaborative Group; Horby P, Lim WS. et al.Dexamethasone in hospitalized patients with Covid-19 – Preliminary report. N Engl J Med (in press), doi: 10.1056/NEJMoa2021436. - PMC - PubMed
1. Kalil AC, Patterson TF, Mehta AK. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med (in press), doi: 10.1056/NEJMoa2031994. - PMC - PubMed
1. Stebbing J, Krishnan V, Bono S. et al.; Sacco Baricitinib Study Group. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med 2020;12:e12697. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

MC_PC_20006/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information